Novo Nordisk begins Phase I trial for secret obesity drug

Novo Nordisk ↗ 1.30% has quietly registered a first-in-human Phase I clinical trial for a previously undisclosed obesity candidate, NNC0721-8060, marking the first public emergence of the experimental program. The company has revealed no details about the drug's molecular target, mechanism of action, or modality.allsci

The randomized, double-blind, parallel-group study (NCT07767175) plans to enroll 142 adults aged 18 to 55 with a body mass index between 27.0 and 34.9 kg/m², divided across three parts. Parts A and B will primarily assess treatment-emergent adverse events, while Part C will measure percentage change in body weight from baseline.allsci

Semaglutide as Internal Benchmark

A notable design choice is the inclusion of semaglutide — the active ingredient in Wegovy and Ozempic — as an active comparator arm alongside placebo. This is unusual for a first-in-human study and will allow Novo Nordisk to benchmark early weight-loss signals against its own established GLP-1 receptor agonist within the same trial.ad-hoc-news+1

The trial is expected to begin in August 2026 at two ICON-operated early-phase sites in Lenexa, Kansas and San Antonio, Texas, with primary completion anticipated in September 2027.allsci

Pipeline Expansion Under Pressure

The registration comes at a time when Novo Nordisk faces intensifying competition in obesity drug development and recent setbacks in diversification efforts. In late July, the company's experimental cardiovascular drug ziltivekimab failed to reduce major adverse cardiovascular events in a late-stage trial, dealing a blow to its push beyond obesity and diabetes.reuters

No prior company announcement, scientific publication, or publicly disclosed preclinical data for NNC0721-8060 has been identified, meaning the trial registration represents the program's first substantive public disclosure. Without knowledge of the drug's target, competitive positioning against other pipeline assets in the crowded obesity pharmacology field remains impossible to assess.allsci

What Comes Next

With enrollment not yet open, the next milestone will be initiation of dosing. The September 2027 primary completion date should yield the first clinical assessment of NNC0721-8060's safety profile and an initial indication of its effect on body weight relative to both placebo and semaglutide.ad-hoc-news+1